How to Stabilize Hyperkalemia in Inpatient Settings
For acute hyperkalemia in hospitalized patients, immediately administer IV calcium (10 mL of 10% calcium gluconate) to stabilize the cardiac membrane within 1-3 minutes, followed by insulin/glucose (10 units regular insulin with 50 mL of 50% dextrose) and nebulized salbutamol (20 mg in 4 mL) to shift potassium intracellularly within 30-60 minutes, then initiate potassium removal strategies including diuretics, potassium binders, or hemodialysis depending on clinical context. 1
Immediate Stabilization Algorithm
Step 1: Cardiac Membrane Stabilization (1-3 minutes)
- Administer IV calcium gluconate 10 mL of 10% solution immediately if ECG changes are present or potassium >6.5 mEq/L 1
- Calcium does NOT lower potassium but prevents life-threatening arrhythmias by reducing membrane excitability
- If no effect within 5-10 minutes, repeat the dose 1
- Critical caveat: ECG changes can be highly variable and nonspecific; absence of ECG changes does NOT exclude severe hyperkalemia 1
Step 2: Intracellular Potassium Shift (30-60 minutes onset)
Administer combination therapy for maximal effect:
IV insulin 10 units with 50 mL of 50% dextrose 1
- Monitor glucose closely to prevent hypoglycemia
- Effect lasts several hours but does NOT remove potassium from body
Nebulized salbutamol 20 mg in 4 mL 1
- Short duration of effect (2-4 hours)
- Can be repeated as needed
- Additive effect when combined with insulin
IV sodium bicarbonate - ONLY in patients with concurrent metabolic acidosis 1
- Not effective as monotherapy
- Has lost favor due to poor efficacy when used alone 2
Step 3: Potassium Removal from Body
Choose based on clinical context:
For Hypervolemic Patients (with preserved kidney function):
- Loop diuretics (furosemide) to enhance renal potassium excretion 1
- Requires adequate residual kidney function to be effective
For Oliguric or ESRD Patients:
- Hemodialysis is definitive treatment 1, 3
- Most effective for severe, refractory hyperkalemia
- Removes potassium from body completely
For All Patients (including those awaiting dialysis):
- Newer potassium binders (preferred over older agents):
Sodium zirconium cyclosilicate (SZC): 10 g three times daily for 48 hours, then 5-15 g daily for maintenance 1
- Onset within 1-2 hours when added to standard therapy
- Can be used in acute setting
- Most common adverse effect: dose-dependent edema
Patiromer: 8.4 g once daily, titrated as needed 1
- Onset approximately 7 hours
- Must be separated from other oral medications by ≥3 hours
- Monitor for hypomagnesemia and potential hypercalcemia
- Most common adverse effects: GI symptoms (constipation, diarrhea)
Critical Monitoring Requirements
- Recheck potassium within 1-2 hours after initial interventions to assess response 4
- Continuous ECG monitoring for patients with severe hyperkalemia or ECG changes
- Monitor for:
- Potassium trajectory
- ECG normalization
- Glucose levels (with insulin therapy)
- Recurrence of hyperkalemia (shifting agents are temporary)
Common Pitfalls to Avoid
Pseudohyperkalemia: Rule out hemolysis, poor phlebotomy technique, or delayed specimen processing before aggressive treatment 1
Relying solely on ECG: ECG changes are not sensitive predictors; laboratory values are more reliable 1
Using sodium polystyrene sulfonate (SPS/Kayexalate): This older resin has limited efficacy in acute settings and carries FDA warning for severe, potentially fatal GI adverse events 2, 5
Forgetting glucose with insulin: Always administer dextrose to prevent hypoglycemia 1
Single intervention approach: Combination therapy (calcium + insulin/glucose + salbutamol) is more effective than monotherapy 1
Post-Stabilization Management
After acute stabilization, immediately address reversible factors 6, 1:
- Review and adjust medications (NSAIDs, potassium-sparing diuretics, excessive RAASi)
- Correct metabolic acidosis if present
- Address constipation
- Evaluate dietary potassium intake (though strict restriction is being reconsidered) 6, 7
Critical principle: Do NOT discontinue RAASi therapy in patients with heart failure or proteinuric kidney disease, as these medications improve mortality outcomes 6, 1. Instead, use potassium binders to maintain RAASi therapy 6.
Reassessment Timeline
- Within 7-10 days: Recheck potassium after any medication adjustments or RAASi dose changes 1
- Within 1 week: Reassess after resolution of acute hyperkalemia if RAASi reinitiation is planned 1
- Ongoing: More frequent monitoring for high-risk patients (CKD, diabetes, heart failure, history of hyperkalemia) 1
The evidence strongly supports this algorithmic approach, with the most recent 2025 European Heart Journal guidelines 6 and 2021 Mayo Clinic Proceedings comprehensive review 1 providing the framework. The key paradigm shift is maintaining disease-modifying therapies (like RAASi) while using newer potassium binders rather than the outdated approach of discontinuing life-saving medications.